Home | Hepatitis C News
HEPATITIS C NEWS
- Virus C Hepatitis and Type 2 Diabetes: A Cohort Study in Southern Italy.
READ NEWS - Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis.
READ NEWS - Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
READ NEWS - Gilead Submits New Drug Application to U.S. FDA For Sofosbuvir for the Treatment of Hepatitis C
READ NEWS - As many as one in 50 people around the world is infected with some type of hepacivirus or pegivirus,
including up to 200 million with hepatitis C virus (HCV), a leading cause of liver failure and liver cancer.
READ NEWS - AMSTERDAM ‐‐ Two years after direct‐acting antiviral drugs for hepatitis C virus (HCV) infection hit the
U.S. market, anemia has been far and away their most significant adverse effect, researchers said
here.
READ NEWS - AMSTERDAM, the Netherlands — A regimen of 3 direct-acting antiviral drugs plus ritonavir and
ribavirin produced sustained virologic response rates in more than 90% of a broad range of patients
infected with hepatitis C 24 weeks after therapy, results from a new clinical trial show.
READ NEWS - Gilead Submits New Drug Application to U.S. Fda for Sofosbuvir for the Treatment Of Hepatitis C
READ NEWS - Sustained Virological Response Linked With Improved Survival for HCV Patients
READ NEWS - Adherence to hepatitis C treatment: unraveling the complexities
READ NEWS - HCV Treatment Pipeline Update
READ NEWS - The Hepatitis‐Fibromyalgia Connection
READ NEWS - Serious and Fatal Skin Reactions to Incivek
READ NEWS - Triple therapy has poor safety in cirrhotic hepatitis C
BOSTON – In patients with chronic hepatitis C virus infections and compensated cirrhosis, a combination of a direct-acting antiviral agent, pegylated interferon, and ribavirin produced high on-treatment virologic response rates ...
READ NEWS - Hepatitis C Reaching Crisis Levels; Requires Coverage for Routine Screenings
WASHINGTON, Nov. 27, 2012 -- Summit on HIV and Viral Hepatitis Charts Priorities to Accelerate Testing, Reduce Disparities in Care
READ NEWS - Abbott Announces Phase 3 Hepatitis C Program Details
Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.
READ NEWS - HCV Drug Combo Promising All on Its Own
A three-drug regimen that eliminated both standard hepatitis C drugs has yielded positive early results in hard-to-treat patients, a researcher reported.
READ NEWS - Simple HCV Regimen shows Promise
A simplified hepatitis C (HCV) regimen with just two oral drugs had promising results in a difficult-to-treat population, a researcher reported here.
READ NEWS - Gilead posts positive results in mid-stage Hepatitis C study
(Reuters) - Gilead Sciences Inc on Saturday reported a 100 percent cure rate using a combination of drugs in a small number of patients with the most common and hardest to treat form of hepatitis C.
READ NEWS - Abbott hepatitis C drugs bring high cure rates in trial
(Reuters) - A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients, Abbott said on Saturday.
READ NEWS - Washington Post Hepatitis & Liver Health Publication
National media coverage is finally happening. Read the articles in this publication for concise information about hepatitis C, CDC recommendations that all baby boomers get tested and much more.
READ NEWS - ATTAIN Study
Clinical research doctors are looking for people with hepatitis C to participate in a clinical research study.
READ NEWS - CDC Now Recommends All Baby Boomers Receive One-Time Hepatitis C Test
New approach will help avert major increases in liver disease and deaths in the U.S.
READ NEWS - DDW: Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity
READ NEWS - Herbal & Dietary Supplements
READ NEWS - Drug Interactions with Hepatitis C Virus NS3/4A Protease Inhibitors and HIV Medications: A Quick Guide for Clinicians
READ NEWS - Telaprevir May Cause Severe Cutaneous Eruptions
READ NEWS - EASL: Telaprevir and Boceprevir Effective but Cause Serious Side Effects in Patients With Cirrhosis
READ NEWS - EASL: Interferon Lambda as Effective as Alfa for Hepatitis C but with Much Better Safety Profile
READ NEWS - EASL: GS‐7977, Daclatasvir, and Asunaprevir Look Good in Interferon‐Free Regimens for Hepatitis C
READ NEWS - Pancreatitis Forces Halt to HCV Drug Trial
READ NEWS - High Cost of Telaprevir Overshadows Clinical Benefits in Patient Subset
Results Based on Cost-Effectiveness Model
READ NEWS - Updated AASLD HCV Guideline Aims To Simplify Use of DAAs:
More Data Needed To Fill Gaps in Understanding
READ NEWS - FDA Update Statin Labels Updated: HCV Protease Inhibitor Contraindication Highlighted
READ NEWS - Federal Guidelines for the Treatment of Hepatitis C and Cirrhosis in Prisons 2012
READ NEWS - The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C
Antibody in U.S. Primary Care Settings
READ NEWS - Treatment of patients with chronic Hepatitis C Virus (HCV) infection with an interferon-free regimen
READ NEWS - An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
READ NEWS - HCV Protease Inhibitor Danoprevir Promising in Early Trial
READ NEWS - DDW: Study Backs HCV Screens for All Boomers
READ NEWS - Telemedicine Puts HCV Care in Hands of PCPs
READ NEWS - Telaprevir (Incivek) Approved
READ NEWS - BOCEPREVIR APPROVED
READ NEWS - 4-Drug Combo with Telaprevir and VX-222 Clears HCV at 12 Weeks
READ NEWS - First Sustained Response Data for Polymerase Inhibitor Mericitabine EASL
READ NEWS - Pegylated Interferon Lambda Boosts Response with Few Side Effects EASL
READ NEWS - Boceprevir Helps Hepatitis C Patients with Cirrhosis EASL
READ NEWS - Statin Boosts Response to Pegylated Interferon/Ribavirin EASL
READ NEWS - Liver Cancer in Cirrhotic Patients Effectively Treated With Radiofrequency Ablation, Study Suggests
READ NEWS - HCV Infection and the Incidence of CKD
READ NEWS - CDC Analysis Recommends Enhanced Acute Hepatitis C Surveillance
READ NEWS - Clinical Virology Results from Telaprevir Phase 3 Study ADVANCE
READ NEWS - Non response to peginterferon alfa and ribavirin in IL28B CC & CT patients can be overcome by high dose continuous interferon alfa-2b administration in combination with ribavirin for chronic hepatitis C
READ NEWS - GI-5005 Therapeutic Vaccine Plus Peg-IFN/Ribavirin Improves Sustained Virologic Response Versus Peg-IFN/Ribavirin In Prior Non-Responders With Genotype 1 Chronic HCV Infection
READ NEWS - Telaprevir in Combination with Peginterferon Alfa2a and Ribavirin for 24 or 48 weeks in Treatment-Naïve Genotype 1 HCV Patients who Achieved an Extended Rapid Viral Response: Final Results of Phase 3 ILLUMINATE Study
READ NEWS - Response-Guided Therapy (RGT) with Boceprevir (BOC) + Peginterferon alfa-2b/Ribavirin (P/R) for Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype (G) 1 Was Similar to a 48-Wk Fixed-Duration Regimen with BOC + P/R in SPRINT-2
READ NEWS - Completely individualized treatment durations with peginterferon-alfa-2b and ribavirin in HCV genotype 1-infected patients and importance of IL28B genotype (INDIV-2 study)
READ NEWS - Long-term Follow-up of Patients with Chronic Hepatitis C Treated with Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin: Interim Analysis of the EXTEND Study
READ NEWS - Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients with advanced chronic hepatitis C: extended follow - up results from the HALT - C Trial
READ NEWS - FDA Issues Guidance for Development of Directing-acting Antiviral Drugs for Hepatitis C
READ NEWS - Highest Rates of Hepatitis C Virus Transmission Found in Egypt
READ NEWS - Vertex hep C drug works on many in 24 weeks: Study
READ NEWS - KERRY & HONDA: Disrupting a deadly disease
READ NEWS - Hispanics And Asians Less Likely To Receive Liver Transplants
READ NEWS - FDA Approves Rapid Test for Antibodies to Hepatitis C Virus
READ NEWS - Vitamin A and Treatment
READ NEWS - Efforts to Up Minority Organ Donations Show Success
READ NEWS - Study Finds Beta Blockers Alone More Effective for First Variceal Bleeding
READ NEWS - Antiviral Therapy during Compensated Cirrhosis Most Cost-Effective Approach Treatment
READ NEWS - Study Finds Poor Compliance with Cirrhosis Surveillance Recommendations Less than 20% of Qualified Patients Are Regularly Monitored
READ NEWS - Peginterferon alfa-2B and Ribavirin for Liver Transplant Patients Yields 30% HCV SVR
READ NEWS - Modest" Results With Nitazoxanide for HCV Genotype 1 Nonresponders
READ NEWS - Study Links Liver Transplantation to Accelerated Cellular Aging
READ NEWS - FDA Considers Expanded Use of HCV Drugs
READ NEWS - Liver Donations from Living Donors Increase 42% after Educational Intervention
READ NEWS - Infectious Disease Screening
READ NEWS - Telaprevir Raises Response Rates in Hepatitis C
READ NEWS - HCV Polymerase Inhibitor VX-222 Demonstrates Good Safety and Antiviral Activity in Treatment-naive Genotype 1 Hepatitis C Patients
READ NEWS - HCV Protease Inhibitor Danoprevir (RG7227/ITMN-191) Shows Antiviral Activity at Lower Doses When Boosted with Ritonavir
READ NEWS - HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse
READ NEWS - Vertex Will Study All-Oral Regimen of HCV Protease Inhibitor Telaprevir plus Polymerase Inhibitor VX-222
READ NEWS - U.S. Doctors Sanction Transplant Criteria for Liver Cancer Patients
READ NEWS - Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies
READ NEWS - Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
READ NEWS - Hepatitis and Liver Cancer: A National Strategy for
Prevention and Control of Hepatitis B and C
READ NEWS - Liver Donations from Living Donors Increase 42% after Educational Intervention
READ NEWS - Vaccines May Lower Viral Load Improve Treatment Response
READ NEWS - African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C
READ NEWS - Metabolic Factors That Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV Patients
READ NEWS - Weight Loss: A Modifiable Lifestyle Parameter That Can Alter HCV Liver Disease Progression
READ NEWS - Silent Epidemic of Viral Hepatitis May Lead to Boom in Serious Liver Disease
READ NEWS - Direct Antivirals Can Beat HCV Without Interferon
READ NEWS - HCV Response Linked Strongly to Gene Variant
READ NEWS - Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), An Investigational, Once-Daily Protease Inhibitor For Hepatitis C
READ NEWS - More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen
READ NEWS - Sprint 1 Study, Phase 2, Boceprevir
READ NEWS - Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
READ NEWS - Coffee Could Stall Liver Disease Progression
READ NEWS - Hepatitis C Drug Development at a Crossroads - Comments from the Editors
READ NEWS - Hypertension and Diabetes Are Concern in Long-Term Care of Liver Transplant Patients
READ NEWS - The FDA has just issued new warnings in the package inserts for alpha interferons
READ NEWS - Women, Blacks, Medicare Recipients Less Likely To Be Evaluated For Liver Transplantation
READ NEWS - New Biomarker Predicts Response to Hepatitis C Treatment
READ NEWS - Protein & Cholesterol May Increase Risk Of Cirrhosis & Hepatocellular Carcinoima
READ NEWS - Weight-Related Factors Tied to Outcomes of Chronic Hepatitis C
READ NEWS - Head-to-Head Trial Finds HCV Regimens Equal
READ NEWS - Interferon and Ribavirin Second-Line Option for Hepatitis C
READ NEWS - DDW: Interferon Has Long-Term Histo Benefits in HCV
READ NEWS - FDA May Restrict Acetaminophen
READ NEWS - Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1
READ NEWS - DDW: Telaprevir Improves HCV Clearance in Resistant Patients
READ NEWS - Hypothyroidism In Women Associated With Liver Cancer
READ NEWS - Sustained Response Seen with New Hepatitis C Drug
READ NEWS - Re-treatment of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated Interferon Alfa-2b (PegIntron)
READ NEWS - Promising Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C
READ NEWS - Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C
READ NEWS - HCV Vaccine Development
READ NEWS - Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
READ NEWS - Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
READ NEWS - Response To Therapy In Chronic Hepatitis C Predicted By 2-Day Results
READ NEWS - Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
READ NEWS - Hepatitis C Linked to Increased Risk of Intrahepatic Cholangiocarcinoma
READ NEWS - Liver Biopsies Indicate Persistent Inflammation and Fibrosis in HCV Antibody Positive People with Undetectable HCV RNA
READ NEWS - Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study with R7128 in Treatment Naive HCV Patients
READ NEWS - Human Genome Sciences Announces Initiation of Phase 2b Trial 0f Albuferon Dosed Monthly in Chronic Hepatitis C
READ NEWS - Although Hepatitis C Treatment Reduces The Virus, Liver Damage Continues
READ NEWS - Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint In Phase 3 Trial In Chronic Hepatitis C
READ NEWS - Pegylated interferon alpha2a is more effective in some hepatitis C patients with specific genotypes than the alpha2b form of the drug, an Italian researcher said
READ NEWS - HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
READ NEWS - Hepatitis C patients may have abnormal blood sugar
READ NEWS - FDA Approves Nexavar for Patients with Inoperable Liver Cancer
READ NEWS - Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years
READ NEWS - Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
READ NEWS - Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients
READ NEWS - Insulin Resistance Independently Associated With Chronic Hepatitis C
READ NEWS - Pathology of Chronic Hepatitis C in Children: Peds-C Trial
READ NEWS - Silymarin (Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non Users
READ NEWS - Acute Hepatitis C Infection and Spontaneous Viral Clearance in Adults and Children
READ NEWS - How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50?
READ NEWS - Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians
READ NEWS - HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C
READ NEWS - Use of Epoetin (EPO) to Manage Anemia in Chronic Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
READ NEWS - Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis
READ NEWS - HCV Care by Liver Specialists or Community-Based Practices: Pro & Con
READ NEWS - Decreased HCV-specific Immunity in African-Americans May Help Explain Poorer Response to Antiviral Therapy
READ NEWS - 400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV
READ NEWS - Liver Stiffness Predicts Portal Hypertension in HCV Cirrhosis
READ NEWS - EASL: Sustained Virologic Response Equals Cure for HCV Infection
READ NEWS - Racial Differences Seen In Steatosis In Patients With Hepatitis C
READ NEWS - New Vaccine Schedule Offers Protection Against Hepatitis A And Hepatitis B
READ NEWS - Interferon Gamma Does Not Reverse Fibrosis in Hepatitis C Patients with Advanced Liver Disease
READ NEWS - Hepatitis C in African Americans
READ NEWS - Three Studies Examine Syringe Exchange Policies in the U.S.
READ NEWS - Short-course Pegylated Interferon for Acute Hepatitis C
READ NEWS - Heavy-Drinking Women with HCV Infection Cut Decade Off Life
READ NEWS - Treatment Response in Cirrhotic Hepatitis C Patients with Portal Hypertension
READ NEWS - Integrating Medical and Mental Health Care Improves Likelihood of Initiation and Adherence to Hepatitis C Treatment
READ NEWS - Rapid Decline of HCV RNA in Patients Treated with VX-950
READ NEWS - Predicting Survival After Liver Transplant
READ NEWS - Patients Who Recover from Hepatitis C Have Lower Risk of Reinfection
READ NEWS - New Therapy Significantly Increases Platelet Count
READ NEWS - Is Hepatitis A and B Screening and Vaccination in Chronic Hepatitis C Patients Effective?
READ NEWS - Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients
READ NEWS
